In the fourth quarter of 2015, we initiated a multinational, multi-center Phase 1b/2 clinical trial of ATYR1940 in adult patients with LGMD2B or FSHD. This international Phase 1b/2 clinical trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and biological activity of weekly and twice weekly intravenous infusions of ATYR1940 in adults with either LGMD2B or FSHD.

We completed enrollment ahead of schedule in May of 2016 with 18 total patients (8 with FSHD and 10 with LGMD), exceeding our stated target enrollment of 16 patients.

We announced results in the fourth quarter of 2016.

Data Release

© 2007 - 2019   aTyr Pharma.   Legal   Privacy Policy